Project granted to Evorion: two million Euro for “Droplet-Based Microfluidics”

Already about a month ago, “our” first start-up biotech company Evorion Biotechnologies GmbH headed by Hans Kleine-Brüggeney, Robert Weingarten and Dr. Sebastian Bühren, was granted a two-million Euro project in the framework of the program “KMU-innovativ: Biotechnologie - BioChance” of the German Federal Ministry of Education and Research, BMBF. This three-year project will allow them to develop their innovative technologies into prototypes, in collaboration with the research groups of Prof. Dr. Jürgen Klingauf (Medical Faculty) and Prof. Dr. Wolfram Pernice (Faculty of Physics) of the University of Münster, and supported by the group of Prof. Dr. Florian Hollfelder from the University of Cambridge. We are not even involved in this project ourselves, but we are still proud to witness the ongoing success story of the Evorion team. But of course, we are not surprised: their microfluidic system allowing multiparametric analysis of complex cell populations at single-cell resolution has an enormous potential to increase the efficiency of immuno-therapies in cancer treatment, to reduce negative side effects, and to allow a personalized evaluation of immuno-therapies. In our own interest: Let’s wish them the best of success, and quickly, so that we can all profit from their results!